SEC For				0747								<u></u>					
FORM 4 UNITED				SIA	STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See						Pursuant to Section 16(a) of the Securities Exchange Act of 1934									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person* Ragosa Mark (Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE, 2 CHURCH STREET					Kiniksa Pharmaceuticals, Ltd. [KNSA] (Check all applic Director Director 3. Date of Earliest Transaction (Month/Day/Year) Officer								r 10% Owner (give title Other (specify				
(Street) HAMILT (City)	CON D	0	HM 11 (Zip)		Line) X Forn Forn						e) <mark>X</mark> Form f	r Joint/Group Filing (Check Applicable filed by One Reporting Person filed by More than One Reporting on					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,			Transaction Disposed Of (I Code (Instr. 5)			f (D) (Instr. 3, 4 and E		5. Amount of 6. Securities Fo Beneficially (D) Owned Following (I) Reported		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code V	Amount	(A) oi (D)	Price	Transact (Instr. 3 a	ion(s)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date ecurity or Exercise (Month/Day/Year		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
				c	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Share Option	\$12.97	09/02/2021			A		44,661		(1)	09/01/2031	Class A Common Shares	44,661	\$0	44,661	D		
Restricted Share Units	(2)	09/02/2021			A		7,444		(3)	(3)	Class A Common Shares	7,444	\$0	7,444	D		

Explanation of Responses:

1. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.

2. Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.

3. The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

<u>/s/ Madelyn Zeylikman,</u>	
Attorney-in-Fact for Mark	09/07/2021
<u>Ragosa</u>	
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.